Last year marked an increase in federal securities class action filings, with plaintiffs filing 212 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019. Life sciences companies remained...more
Life sciences companies were popular targets of class action securities lawsuits in 2018.
In the most recent edition of our annual survey, Dechert litigators David H. Kistenbroker, Joni S. Jacobsen and Angela M. Liu examine...more
2/13/2019
/ Anti-Kickback Statute ,
Class Action ,
Clinical Trials ,
FDA Approval ,
Fraud ,
Life Sciences ,
Material Misstatements ,
Mismanagement ,
Misrepresentation ,
Popular ,
Risk Management ,
Risk Mitigation ,
Securities Fraud ,
Securities Litigation ,
Stock Drop Litigation ,
Surveys
In a decision that has important implications for both plaintiffs and defendants in securities class actions, the Supreme Court of the United States in Halliburton Co. v. Erica P. John Fund, Inc. (Halliburton II), No. 13-317...more